Immunohistochemical staining of CA 50antigen in human bladder cancer

医学 免疫组织化学 染色 膀胱癌 病理 转移 癌症 膀胱 泌尿科 内科学
作者
P Lipponen,Matti Eskelinen,Yrjö Collan
出处
期刊:Urology [Elsevier BV]
卷期号:38 (2): 163-169 被引量:9
标识
DOI:10.1016/s0090-4295(05)80080-9
摘要

The immunohistochemical detection of tumor marker CA 50 was studied in bladder cancer of WHO grades I–III. The material consisted of tumors in 83 patients and the mean clinical follow-up time was thirteen years (range 9.6–22 years). The fraction of CA 50-positive cells (FPtot) in microscopic image was scored 0–100 percent. Also the maximally staining region was selected, and the fraction of CA 50-positive cells in this region was scored 0–100 percent (FPmax). The average staining intensity of CA 50-positive cells was scored from 0 to 3 in the whole section (ASItot) and in the maximally staining area (ASImax). The inverse relation between histologic grade, FPtot (p = 0.0001), and ASItot (p = 0.006) was statistically significant. FPtot (p = 0. 039) and ASItot (p = 0.018) were also inversely related to clinical stage. Occurrence of metastasis during the follow-up was associated with low CA 50 positivity (FPtot, p = 0.003; ASItot, p = 0.002). The lower the staining intensity or the lower the fraction of CA 50-positive cells, the more aggressive was the tumor. In survival analysis, low FPtot (p = 0.002) and ASItot (p = 0.007) values were related to high risk of bladder cancer death. The results show that immunohistochemical staining of bladder tumor specimens with CA 50 can be used to predict bladder cancer aggressiveness and survival.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
llllllb发布了新的文献求助10
1秒前
ccyrichard完成签到,获得积分10
1秒前
1秒前
mds发布了新的文献求助10
3秒前
CMD完成签到 ,获得积分10
3秒前
正版DY发布了新的文献求助10
3秒前
3秒前
Dank1ng完成签到,获得积分10
4秒前
小二郎应助安若采纳,获得10
4秒前
4秒前
彭于晏应助清明采纳,获得10
5秒前
YLL完成签到,获得积分10
5秒前
木梨子完成签到,获得积分10
6秒前
橙子发布了新的文献求助10
6秒前
6秒前
文艺的雨完成签到,获得积分10
7秒前
8秒前
huahua完成签到,获得积分10
8秒前
英俊的铭应助dry采纳,获得10
9秒前
小橘完成签到,获得积分10
10秒前
10秒前
琥1完成签到,获得积分10
10秒前
maguodrgon发布了新的文献求助10
11秒前
虚幻的亦旋完成签到,获得积分10
11秒前
13秒前
量子星尘发布了新的文献求助10
14秒前
Babytucky发布了新的文献求助10
14秒前
柴鱼完成签到,获得积分10
16秒前
零琳完成签到 ,获得积分20
17秒前
雪王完成签到,获得积分10
17秒前
18秒前
18秒前
NexusExplorer应助炫彩小陈采纳,获得10
18秒前
21秒前
顾矜应助mds采纳,获得10
23秒前
24秒前
kaier完成签到 ,获得积分0
25秒前
25秒前
26秒前
27秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5142180
求助须知:如何正确求助?哪些是违规求助? 4340425
关于积分的说明 13517521
捐赠科研通 4180348
什么是DOI,文献DOI怎么找? 2292405
邀请新用户注册赠送积分活动 1293003
关于科研通互助平台的介绍 1235514